Claim 50 (currently amended): A method in accordance with claim ~~claims 30 or 32~~ 30 in which said D,α tocopherol is present in the form of a member selected from the group consisting of D,α tocopherol succinate, D, α-tocopherol nicotinate, D, α-tocopherol picolinate, D,α tocopherol acetate, and tocotrienol.

Claim 51 (currently amended): A method in accordance with claim ~~claims 40 or~~ 50 in which said tocotrienol is present in the form of a member selected from the group consisting of tocotrienol succinate, tocotrienol nicotinate, tocotrienol picolinate, and tocotrienol acetate.

Claim 52 (original): A method in accordance with claim 36 in which said chromium is in the form of a member selected from the group consisting of chromium dinicotinate, and chromium tripicolinate.

Claim 53 (currently amended): A method for treating a patient who is undergoing sulfonylurea therapy for the prevention, management, and clinical amelioration of insulin resistance and type 2 diabetes and conditions giving rise thereto, to reduce undesirable physiological side effects, and enhance the therapeutic effectiveness, of said sulfonylurea therapy, said method comprising administering to said patient a unit dosage form comprising as active ingredients:

(a) L-carnitine,

(b) Ascorbic acid,

(c) Choline,

(d) ~~(e)~~ Taurine,

(e) ~~(f)~~ Folic Acid, and

(f) ~~(g)~~ Magnesium.

Claim 54 (original): A method in accordance with claim 53 in which said active ingredients are formulated as a substantially homogeneous tablet or capsule that releases all of said active ingredients into the stomach upon ingestion for contact with gastric fluid.